1.56
price up icon0.65%   0.01
after-market After Hours: 1.57 0.01 +0.64%
loading
Repare Therapeutics Inc stock is traded at $1.56, with a volume of 83,584. It is up +0.65% in the last 24 hours and up +13.87% over the past month. Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.
See More
Previous Close:
$1.55
Open:
$1.56
24h Volume:
83,584
Relative Volume:
0.25
Market Cap:
$66.91M
Revenue:
$51.13M
Net Income/Loss:
$-93.80M
P/E Ratio:
-0.6996
EPS:
-2.23
Net Cash Flow:
$-129.10M
1W Performance:
+3.31%
1M Performance:
+13.87%
6M Performance:
+27.87%
1Y Performance:
-60.00%
1-Day Range:
Value
$1.545
$1.58
1-Week Range:
Value
$1.50
$1.58
52-Week Range:
Value
$0.89
$4.22

Repare Therapeutics Inc Stock (RPTX) Company Profile

Name
Name
Repare Therapeutics Inc
Name
Phone
(857) 412-7018
Name
Address
7171 FREDERICK BANTING, SAINT-LAURENT, QC
Name
Employee
129
Name
Twitter
@reparerx
Name
Next Earnings Date
2023-08-09
Name
Latest SEC Filings
Name
RPTX's Discussions on Twitter

Compare RPTX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
RPTX
Repare Therapeutics Inc
1.56 66.48M 51.13M -93.80M -129.10M -2.23
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Repare Therapeutics Inc Stock (RPTX) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-09-23 Upgrade Stifel Hold → Buy
Feb-03-23 Downgrade Morgan Stanley Overweight → Equal-Weight
Jan-06-23 Initiated CapitalOne Overweight
Apr-12-22 Downgrade Stifel Buy → Hold
Mar-17-22 Resumed Goldman Buy
Sep-23-21 Initiated Stifel Buy
Sep-13-21 Initiated H.C. Wainwright Buy
Jun-28-21 Initiated Guggenheim Buy
Mar-01-21 Initiated Berenberg Buy
Oct-28-20 Initiated Northland Capital Outperform
Jul-14-20 Initiated Cowen Outperform
Jul-14-20 Initiated Goldman Neutral
Jul-14-20 Initiated Morgan Stanley Overweight
Jul-14-20 Initiated Piper Sandler Overweight
View All

Repare Therapeutics Inc Stock (RPTX) Latest News

pulisher
11:15 AM

Repare Therapeutics (NASDAQ:RPTX) Trading 0.6% Higher – What’s Next? - Defense World

11:15 AM
pulisher
02:45 AM

Repare Therapeutics (NASDAQ:RPTX) Trading 0.6% HigherWhat's Next? - MarketBeat

02:45 AM
pulisher
Jul 25, 2025

Is Repare Therapeutics Inc. a good long term investmentMassive portfolio appreciation - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Will Repare Therapeutics Inc. stock benefit from interest rate changesExplosive earnings growth - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 25, 2025

Why Repare Therapeutics Inc. stock is on top investor watchlistsUnrivaled growth potential - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 25, 2025

What analysts say about Repare Therapeutics Inc. stock outlookMarket-leading growth rates - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 24, 2025

What drives Repare Therapeutics Inc. stock priceFree Wealth Planning Blueprint - Autocar Professional

Jul 24, 2025
pulisher
Jul 22, 2025

What analysts say about Repare Therapeutics Inc. stockPowerful growth strategies - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Why Repare Therapeutics Inc. stock attracts strong analyst attentionFree Access to Community - Newser

Jul 22, 2025
pulisher
Jul 22, 2025

Repare Therapeutics Inc. Stock Analysis and ForecastUnprecedented growth rates - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 19, 2025

what makes repare therapeutics inc. stock price move sharplyLow Risk Profit Ideas - Newser

Jul 19, 2025
pulisher
Jul 18, 2025

Layoff Tracker: Following Challenges With DMD Therapy, Sarepta Will Cut 500 Employees - BioSpace

Jul 18, 2025
pulisher
Jul 16, 2025

Repare Therapeutics Jumps 15% After $10M Licensing Deal With Debiopharm - Yahoo Finance

Jul 16, 2025
pulisher
Jul 16, 2025

How Repare Therapeutics Inc. stock performs during market volatilityBig Profit Small Risk Alerts - Newser

Jul 16, 2025
pulisher
Jul 16, 2025

Repare Therapeutics Jumps 15% After $10M Licensing Deal With Deb - GuruFocus

Jul 16, 2025
pulisher
Jul 16, 2025

Repare Therapeutics Licenses Lunresertib to Debiopharm for Worldwide Development. - AInvest

Jul 16, 2025
pulisher
Jul 16, 2025

Deal Watch: Debiopharm Takes On Precision Oncology Drug From Repare Collab - insights.citeline.com

Jul 16, 2025
pulisher
Jul 16, 2025

Repare inks licensing deal with Debiopharm for lunresertib - The Pharma Letter

Jul 16, 2025
pulisher
Jul 16, 2025

Repare Therapeutics Jumps After Hours On $267M Global Licensing Deal With Debiopharm; Retail Traders Rush In - Stocktwits

Jul 16, 2025
pulisher
Jul 16, 2025

how repare therapeutics inc. stock performs during market volatilityFast Moving Stock Alerts - Newser

Jul 16, 2025
pulisher
Jul 16, 2025

Repare Therapeutics' Lunresertib Deal: A Strategic Pivot to Unlock Oncology Potential and Near-Term Catalysts - AInvest

Jul 16, 2025
pulisher
Jul 16, 2025

Repare Therapeutics stock surges after $10M licensing deal with Debiopharm By Investing.com - Investing.com South Africa

Jul 16, 2025
pulisher
Jul 15, 2025

What makes Repare Therapeutics Inc. stock price move sharplyHigh Reward Risk Balanced Trading - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Repare Therapeutics stock surges after $10M licensing deal with Debiopharm - Investing.com Nigeria

Jul 15, 2025
pulisher
Jul 15, 2025

Repare Therapeutics Inc. Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib - MarketScreener

Jul 15, 2025
pulisher
Jul 15, 2025

Repare Therapeutics (RPTX) Secures Global Licensing Deal with Debiopharm | RPTX Stock News - GuruFocus

Jul 15, 2025
pulisher
Jul 15, 2025

Repare Therapeutics enters exclusive worldwide licensing agreement with Debiopharm for Lunresertib - MarketScreener

Jul 15, 2025
pulisher
Jul 15, 2025

Repare Therapeutics licenses PKMYT1 inhibitor to Debiopharm for $10 million - Investing.com Nigeria

Jul 15, 2025
pulisher
Jul 15, 2025

Repare Therapeutics licenses PKMYT1 inhibitor to Debiopharm for $10 million By Investing.com - Investing.com South Africa

Jul 15, 2025
pulisher
Jul 15, 2025

Repare Therapeutics jumps on cancer drug licensing deal - TradingView

Jul 15, 2025
pulisher
Jul 15, 2025

Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib | RPTX Stock News - GuruFocus

Jul 15, 2025

Repare Therapeutics Inc Stock (RPTX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Cap:     |  Volume (24h):